On June 18, 2019 Alligator Bioscience (Nasdaq Stockholm: ATORX), reported that the company has submitted an application (Clinical Trial Authorization, CTA) for permission to start a clinical phase I study for the wholly-owned 4-1BB antibody ATOR-1017 , which is being developed for the treatment of spread cancer (Press release, Alligator Bioscience, JUN 18, 2019, View Source [SID1234537140]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ATOR-1017 is an immune-activating antibody (IgG4) that activates tumor-specific T cells and NK cells via the co-stimulatory receptor 4-1BB. T cells and NK cells are capable of detecting and killing tumor cells, making 4-1BB an extremely attractive target for cancer immunotherapy.
ATOR-1017 has a unique profile, among other things, because the immune-activating effect is enhanced in environments where there are many immune cells, which is particularly prevalent in tumors. This creates opportunities for a powerful, tumor-localized immune activation that can reduce the side effects of the patient.
The upcoming Phase I study is a dose determination study in patients with spread cancer, and this is the first time that ATOR-1017 has been evaluated in humans. The study will be conducted at three different clinics in Sweden and cover up to 50 patients. The primary objective of the study is to investigate the safety and tolerability of ATOR-1017 and to establish a recommended dose for subsequent phase II studies.
"We look forward to starting the patient recruitment as soon as the application for ATOR-1017 is approved by the authorities. Our data show that the antibody has the potential to provide a powerful and long-lasting immune response, and even immunity to cancer, while minimizing the side effects by tumor-directed immune activation. This will be our third drug candidate to initiate clinical development and a significant milestone in our work to develop the next generation of immunotherapies against cancer, "says Per Norlén, CEO of Alligator Bioscience.
For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Phone: +46 46 540 82 06
E-mail: [email protected]
The information was submitted, through the agency of the above contact person, for publication on June 18, 2019, at 16:15.